H_1受体拮抗剂治疗常年变应性鼻炎的比较

Effect comparison of H_1-receptor antagonists in the treatment for perennial allergic rhinitis

目的观察常用第二代H1受体拮抗剂治疗常年变应性鼻炎的疗效和安全性。方法将符合纳入标准的105例患者随机分为咪唑斯汀、氯雷他定、西替利嗪3组,每组35例,予相应药物10mg/d,治疗时间均为28d。记录症状体征评分、患者自评变化及不良反应情况。结果3种药物均对过敏症状有明显的抑制效果。其中咪唑斯汀在1h与2周时疗效优于氯雷他定和西替利嗪,且在眼痒症状控制以及安全性上有优势。西替利嗪镇静效果强于其他2种药物。结论3种药物应用于常年变应性鼻炎均有较好的疗效,但咪唑斯汀在起效迅速性和安全性上有优势。临床应注意个体化治疗,并注意避免严重并发症的发生。

Objective To compare the effect and safety of the second generation Hl -receptor antagonists in the treatment for perennial allergic rhinitis. Methods A randomized, single-blinded, controlled trial of mizolastine, loratadine and cetirizine was performed in the treatment for perennial allergic rhinitis. A total number of 105 patients was involved in this trial, and 35 cases were included in every group. Each patient was given 10 rag/d of the proper drug. Treatment duration was 28 days. Regular records of the symptom score reducing index （SSRI） and visual analogue scale （VAS） were made. Results Effect assessment based on SSRI showed that although all the three drugs had significant repressive effect on allergic symptoms, mizolastine excelled in the onehour and two- week efficacy, especially in the alleviation of eyeitch symptom. Cetirizine had better sedative effect than the other two drugs. Conclusion All the three drugs are effective in the treament for perennial allergic rhinitis while mizolastine is superior in rapidity and security to the other two. Attention should be paid to the individual treatment and severe complications must be avoided in clinic application.